P16-CD8-Ki67 Triple Algorithm for Prediction of CDKN2A Mutations in Patients with Multiple Primary and Familial...

Area of Science:

• Oncology
• Genetics
• Immunohistochemistry

Background:

• Melanoma is a growing global health concern, projected to be the second most common US malignancy by 2040.
• The CDKN2A gene, specifically p16INK4a, is crucial for cell cycle regulation and is frequently mutated in familial melanomas (FM).
• Genetic testing for CDKN2A mutations can be costly, posing a barrier for patients with multiple primary melanomas (MPM) and FM.

Purpose of the Study:

• To develop a cost-effective immunohistochemical scoring system to predict CDKN2A mutational status in melanoma.
• To classify MPM and FM patients based on their likely mutational status, thereby reducing the need for extensive genetic testing.
• To assess the utility of p16, CD8, and Ki67 as biomarkers for melanoma evolution and prognosis.

Main Methods:

• A retrospective study of 23 MPM and FM patients.
• Immunohistochemical assessment of p16, CD8, and Ki67 expression in tumor samples.
• Analysis of the association between immunohistochemical parameters and genetic CDKN2A status.

Main Results:

• A scoring system using p16, CD8, and Ki67 achieved 100% sensitivity and 94.11% specificity in identifying melanomas with homozygous CDKN2A deletions (score >= 9/10).
• Individual markers (p16, CD8, Ki67) showed prognostic and evolutionary significance.
• The developed algorithm provides a valuable auxiliary diagnostic tool for predicting mutational status.

Conclusions:

• Immunohistochemical markers p16, CD8, and Ki67 are valuable indicators of melanoma progression.
• The proposed scoring system offers a cost-effective method for predicting CDKN2A homozygous deletions in MPM and FM.
• This approach can significantly reduce healthcare costs associated with genetic testing for melanoma patients.